A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial) by Grigg, Matthew J. et al.
A study protocol for a randomised open-
label clinical trial of artesunate-meﬂoquine
versus chloroquine in patients with non-
severe Plasmodium knowlesimalaria in
Sabah, Malaysia (ACT KNOW trial)
M J Grigg,1,2 T William,2,3,4 P Dhanaraj,4,5 J Menon,4 B E Barber,1,2
L von Seidlein,1,6 G Rajahram,2,3 R N Price,1,7 N M Anstey,1,2,8 T W Yeo1,2,9
To cite: Grigg MJ, William T,
Dhanaraj P, et al. A study
protocol for a randomised
open-label clinical trial of
artesunate-mefloquine versus
chloroquine in patients with
non-severe Plasmodium
knowlesimalaria in Sabah,




▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2014-006005).
NMA and TWY contributed
equally.
Received 30 June 2014
Accepted 17 July 2014






Introduction: Malaria due to Plasmodium knowlesi is
reported throughout South-East Asia, and is the
commonest cause of it in Malaysia. P. knowlesi
replicates every 24 h and can cause severe disease and
death. Current 2010 WHO Malaria Treatment Guidelines
have no recommendations for the optimal treatment of
non-severe knowlesi malaria. Artemisinin-combination
therapies (ACT) and chloroquine have each been
successfully used to treat knowlesi malaria; however,
the rapidity of parasite clearance has not been
prospectively compared. Malaysia’s national policy for
malaria pre-elimination involves mandatory hospital
admission for confirmed malaria cases with discharge
only after two negative blood films; use of a more
rapidly acting antimalarial agent would have health cost
benefits. P. knowlesi is commonly microscopically
misreported as P. malariae, P. falciparum or P. vivax,
with a high proportion of the latter two species being
chloroquine-resistant in Malaysia. A unified ACT-
treatment protocol would provide effective blood stage
malaria treatment for all Plasmodium species.
Methods and analysis: ACT KNOW, the first
randomised controlled trial ever performed in knowlesi
malaria, is a two-arm open-label trial with enrolments
over a 2-year period at three district sites in Sabah,
powered to show a difference in proportion of patients
negative for malaria by microscopy at 24 h between
treatment arms (clinicaltrials.gov #NCT01708876).
Enrolments started in December 2012, with completion
expected by September 2014. A total sample size of
228 is required to give 90% power (α 0.05) to
determine the primary end point using intention-to-
treat analysis. Secondary end points include parasite
clearance time, rates of recurrent infection/treatment
failure to day 42, gametocyte carriage throughout
follow-up and rates of anaemia at day 28, as
determined by survival analysis.
Ethics and dissemination: This study has been
approved by relevant institutional ethics committees in
Malaysia and Australia. Results will be disseminated to
inform knowlesi malaria treatment policy in this region
through peer-reviewed publications and academic
presentations.
Trial registration number: NCT01708876.
INTRODUCTION
Naturally acquired infections with Plasmodium
knowlesi, the ﬁfth human malaria, are
growing.1 Since 2004, increasing numbers of
cases have been reported from residents and
returned travellers predominantly from
Malaysia and throughout South-East Asia.2–11
Cases coincide with the geographic distribu-
tion of its natural simian hosts (long-tailed and
pig-tailed macaques) and Anopheles leucosphyrus
group mosquito vector.12–14 Despite the
increase in reported cases, difﬁculties with
microscopic diagnosis and a lack of PCR-based
epidemiological surveillance studies
Strengths and limitations of this study
▪ All age demographics known to acquire
Plasmodium knowlesi malaria will be eligible for
enrolment, at relevant district referral sites where
treatment is normally given.
▪ The primary intention-to-treat analysis will appro-
priately evaluate rapidity of parasite clearance and
associated health economic benefits; however,
secondary analyses may not show a clinically
useful difference in treatment failure at 42 days in
the absence of known resistance to the study
drugs.
▪ This trial addresses a knowledge gap in knowlesi
malaria, with no previous randomised controlled
trials in P. knowlesi infection to determine
optimal treatment. If ACT is shown to be super-
ior to chloroquine, it would support a national
policy change to a unified ACT treatment proto-
col which would provide effective blood stage
malaria treatment for all Plasmodium species.
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throughout South-East Asia mean the true disease burden
is underestimated. P. knowlesi is microscopically misidenti-
ﬁed as P. malariae and P. falciparum due to morphological
similarities in the late trophozoite and early ring stages,
respectively,14 and is also misreported as P. vivax.15 In
Eastern Malaysia, multiple studies have shown that for
cases microscopically reported as ‘P. malariae’, <1% of
these are conﬁrmed when tested by PCR, with the vast
majority being P. knowlesi.6 16–21 The rise in zoonotic
P. knowlesi cases has occurred at the same time that notiﬁ-
cations of P. falciparum and P. vivax are decreasing due to
an effective national Malaria Control Program in
Malaysia.22 P. knowlesi is now the most common cause of
malaria in Malaysia, with minimum estimates of around
2268 cases (including those reported as ‘P. malariae’ in
Eastern Malaysia) from public health microscopy notiﬁca-
tions in 2012 alone.23
Misdiagnosis of P. knowlesi has concerning treatment
implications, as unlike P. malariae, knowlesi malaria has a
rapid 24 h replication rate and can cause hyperparasitae-
mia, severe complications and fatal outcomes.21 24–26
The inadvertent use of chloroquine (CQ) for widely
CQ-resistant P. falciparum or P. vivax in this region may
lead to treatment failure, with a consequent higher risk
of severe disease or death. In addition, misreporting
with P. vivax may have implications for the correct initi-
ation of liver-stage P. vivax eradication.
Treatment of non-severe knowlesi malaria
Initial observational and retrospective studies have sug-
gested that both CQ and artemisinin-combination
therapy (ACT) are effective therapies for non-severe
P. knowlesi infection.16 21 25 27 28 Case reports predomin-
antly from returned travellers to South-East Asia also
document non-severe knowlesi malaria responding well
to conventional antimalarials such as CQ, meﬂoquine
(MQ), atovaquone with proguanil, doxycycline and
quinine.2 4 29–35 However, to date there have been no
prospective randomised trials to determine the optimal
treatment of non-severe P. knowlesi infection in Malaysia,
and there are no current recommendations on how to
treat non-severe P. knowlesi infection in the current 2010
WHO Malaria Treatment Guidelines.36
Artesunate-mefloquine
Artesunate (AS)-MQ is a common and widely available
ACT, and along with artemether-lumefantrine (A-L) is
one of only two ﬁrst-line WHO recommended options
for the treatment of non-severe P. falciparum infection
that are registered in Malaysia and produced according
to international good manufacturing practice standards.
ACTs are the current mainstay of malaria elimination
efforts,36 with a mechanism of action resulting both in a
rapid reduction in parasite mass and resolution of clin-
ical features, while the long-acting component elimi-
nates residual parasites and delays the development of
de novo resistance.37 38 Safety and tolerability of all ACTs
are dependent on their partner drug39 and while
gastrointestinal and self-limiting neuropsychiatric
adverse events (AESs) have been reported with MQ,
multiple safety and efﬁcacy trials have recommended its
use in adults and children for non-severe falciparum
malaria.40–42 Owing to concerns over the safety of MQ in
the ﬁrst trimester of pregnancy43 and its use in patients
with pre-existing psychiatric disorders or those who have
previously had cerebral malaria, it is currently not
advised for these groups.39
The initial reported use of ACT for knowlesi malaria
was from our retrospective study at a tertiary referral hos-
pital in Sabah, where a small sample of 8 of 34 patients
with PCR-conﬁrmed non-severe P. knowlesi infection were
treated with oral A-L. Median microscopic parasite clear-
ance time was 1 day (range 0–3), which was signiﬁcantly
faster than those receiving CQ (median 2.5 days, range
1–3, p=0.01).25 Our subsequent prospective study at the
same site documented 109 knowlesi malaria patients suc-
cessfully treated with A-L, with no recurrences identiﬁed.
Unpublished data from this study showed that of the
patients with non-severe P. knowlesi malaria enrolled,
51 received A-L monotherapy, with a median parasite
clearance time of 2 days.21 There are no published series
of other ACTs used in the treatment of P. knowlesi infec-
tion, although currently both AS-MQ and A-L are being
used in Sabah for non-severe P. knowlesi and P. falciparum
malaria, including in children >5 kg, as recommended
by local guidelines. In vitro studies using MQ have not
been conclusive.44 Clinically, however, MQ as a single
agent has been used in the successful treatment of a
Swedish traveller returning from Sarawak, Malaysia with
PCR-conﬁrmed non-severe P. knowlesi malaria and 0.1%
infected erythrocytes in 2009.29 However, oral MQ was
not effective when used as an initial monotherapy in a
case reported from Peninsular Malaysia with severe
disease and 1% infected erythrocytes.45 Current WHO
2013 management of severe malaria guidelines recom-
mend intravenous AS and not oral therapy (with any
drug) for patients meeting severe malaria criteria due to
any Plasmodium species.46 The long half life of MQ of
around 14 days also means when used as the partner
drug in an ACT for non-severe malaria caused by other
Plasmodium species such as P. vivax, there is a signiﬁcant
reduction compared to A-L in the day 42 treatment
failure rate.44 45
Chloroquine
CQ with primaquine was initially suggested to have
favourable treatment outcomes for non-severe P. knowlesi
human infections after a retrospective review of patients
from Kapit Hospital in Sarawak in 2004.16 Following this,
a prospective observational study conducted at the same
site between 2006 and 2007 administered CQ as a total
base dose of 25 mg/kg and primaquine as a gametocidal
agent to 73 patients with non-severe PCR-conﬁrmed
P. knowlesi malaria. This resulted in a median fever clear-
ance of 26 h, mean times to 50% and 90% microscopic
parasite clearance of 3.1 and 10.3 h, respectively, and a
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median PCR-adjusted clearance time of 3 days. None of
the 60 patients who completed the 28-day follow-up
demonstrated any evidence of resistance, reinfection or
recrudescence.27 A further 11 patients with non-severe
P. knowlesi malaria conﬁrmed by PCR (including seven
microscopically misdiagnosed initially as P. vivax) from a
prospective study at a tertiary site in Sabah were success-
fully treated with CQ with or without primaquine.21
Rationale for the trial
While ACT and CQ have each been successfully used to
treat knowlesi malaria, the rapidity of parasite clearance
has not been prospectively compared. Malaysian Ministry
of Health national policy in the malaria pre-elimination
phase involves mandatory hospital admission for all
patients with conﬁrmed malaria with hospital discharge
only permitted after two negative blood ﬁlms.47 Use of a
more rapidly acting antimalarial agent would therefore
allow earlier hospital discharge and have health cost ben-
eﬁts. A switch to a uniﬁed ACT-treatment protocol would
avoid ineffectual treatment with CQ in the event of
P. knowlesi being misdiagnosed as P. falciparum or P. vivax,
both CQ-resistant in Malaysia. As ACTs are already being
used for treating P. falciparum and are recommended for
the increasingly CQ-resistant P. vivax found in South-East
Asia,48 the potential beneﬁt of a uniﬁed treatment policy
to facilitate prompt and effective treatment of all
Plasmodium species requires evidence for ACT also being
optimal treatment for P. knowlesi infection.
AIM AND OBJECTIVES
We aim to test whether the ﬁxed combination of AS-MQ
is superior to CQ in order to deﬁne the optimal treat-
ment for non-severe P. knowlesi infection in adults and
children.
The primary end point is the therapeutic efﬁcacy of
AS-MQ versus CQ, as deﬁned by the assessment of
microscopic P. knowlesi parasite clearance 24 h after initi-
ation of treatment. Secondary end points will include
parasite clearance time, including at days 2 and 42. True
treatment failure rates require a 42-day follow-up period
as recommended by WHO antimalarial efﬁcacy and
resistance monitoring guidelines.49 Prevalence of
anaemia at day 28 will also be assessed in order to
enable comparisons over a similar time frame to studies
looking at the use of ACT for other malaria species and
the impact on anaemia-associated morbidity.42 Presence
of gametocytes at follow-up will also be assessed to deter-
mine any post-treatment transmission beneﬁt as seen in
other malarial species treated with ACT.50
Speciﬁc aims include:
▸ Parasite clearance time of P. knowlesi infection.
▸ Length of hospital inpatient stay and estimated cost
to health sector.
▸ Rates of recurrent infection/treatment failure at day
42.
▸ Occurrence of anaemia at day 28 when using AS-MQ
versus CQ.
▸ P. knowlesi gametocyte carriage throughout follow-up
when using AS-MQ versus CQ.
▸ Frequency of complications throughout follow-up
when using AS-MQ versus CQ.
▸ Rates of P. knowlesi recurrence in a 1-year follow-up
period.
▸ Utility of rapid diagnostic tests (RDTs) in the diagno-
sis of P. knowlesi infection.
TRIAL DESIGN
Design and study sites
This is a two-arm, randomised, open-label trial to be
conducted at Kudat, Kota Marudu and Pitas District
Hospitals in Sabah, Malaysia (see ﬁgure 1) over a 3- year
period, which will be powered to determine the optimal
treatment for non-severe P. knowlesi infection.
Trial population
Male and female patients with acute, non-severe
P. knowlesi malaria who present to Kudat, Kota Murudu
and Pitas District Hospitals.
Inclusion criteria
▸ Male and female patients at least 1 year of age and
weighing more than 10 kg.
▸ Microscopic diagnosis of P. knowlesi (including micros-
copy result of P. malariae).
▸ Negative P. falciparum malaria RDT (histidine-rich
protein 2).
▸ Fever (temperature ≥37.5°C) or history of fever in
the past 48 h.
▸ Able to participate in the trial and comply with the
clinical trial protocol.
▸ Written informed consent to participate in the trial.
▸ Subsequent PCR conﬁrmation of P. knowlesi monoin-
fection; including patients initially enrolled and ran-
domised in concurrent P. vivax randomised
controlled trial using same study design (clinicaltrials.
gov #NCT01708876).
Exclusion criteria
▸ Clinical or laboratory criteria for severe malaria,
including warning signs, requiring parenteral treat-
ment according to modiﬁed WHO 2010 criteria.21
▸ Parasitaemia >20 000/μL, a parasite threshold asso-
ciated with increased risk of severe malaria in P. know-
lesi infection.21
▸ Inability to tolerate oral treatment.
▸ Concomitant infection with any other malaria
species.
▸ Pregnancy or lactation.
▸ Unable or unwilling to use contraception during
study period.
▸ Known hypersensitivity or allergy to artemisinin
derivatives.
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▸ Serious underlying disease (cardiac, renal or
hepatic).
▸ Received antimalarials in previous 2 months.
▸ Previous psychiatric illness or epilepsy.
▸ Previous episode of cerebral malaria.
Sample size
We expect that 55% of study participants treated with
CQ will remain parasitaemic 24 h after the start of treat-
ment in contrast to 33% of study participants treated
with AS-MQ.25 27 A trial that will have 90% power to
falsify the Null hypothesis: “there is no signiﬁcant
difference in parasite clearance between artesunate-
meﬂoquine and chloroquine at 24 hours” with a signiﬁ-
cance level (α) of 0.05 requires 114 participants in each
arm or 228 trial participants. It is assumed that 10% of
study participants cannot be followed up for 42 days.
Therefore, we plan to recruit 256 trial participants.
Duration and size of trial
Total duration of the trial is 36 months, with an enrol-
ment period of 24 months. Individual participation
requires follow-up clinic visits after discharge from hos-
pital on days 7, 14, 28 and 42 post-treatment, and tele-
phone contact, when possible, to assess for malaria
recurrence up to a total period of 12 months. The
number of trial participants required is 256 (each
arm=128).
Treatment allocation
An independent statistician will use computer-generated
randomisation to generate blocks of patient numbers for
each treatment in the separate arms. Each code will be
given a sealed opaque envelope which will contain that
patient’s treatment group and which will only be opened
by a study nurse when a patient has been allocated a
code number.
Test drugs
Both study drugs are currently registered and available
in Malaysia, and approved for use by the Malaysian
Ministry of Health. The choice of drugs, including their
administration and dosing have all been chosen to
mimic existing local protocols and conditions in order
Figure 1 Map of study sites.
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to ensure the data gathered are relevant to the clinical
setting in which the drugs will be used.
▸ Artequin (Mepha Ltd, Aesch, Switzerland) consisting
of two different ﬁxed dose tablet blister packs:
600/1500–three tablets of AS 200 mg, six tablets of
MQ hydrochloride 275 mg equivalent to MQ 250 mg
base;
300/750–three tablets of AS 100 mg, three tablets of
MQ 250 mg base.
▸ Artequin Paediatric: a ﬁxed dose formulation of gran-
ules containing: AS 50 mg and MQ 125 mg per dose.
▸ CQ: consisting of 155 mg tablets.
AS-MQ dosing
The safety and efﬁcacy of AS-MQ in the treatment of
non-severe malaria due to other Plasmodium species is
based on a dose of AS 4 mg/kg/day for 3 days51 and a
total MQ dose of 25 mg/kg split over either days 2
and 3, or equally over all 3 days, as this leads to
increased bioavailability and reduces risk of vomiting.41 52
The dosages of the AS-MQ combinations to be adminis-
tered in this study are based on these target weight
dependent calculations and are consistent with current
WHO36 and Malaysian Ministry of Health treatment
guidelines (see ﬁgure 2).47
CQ dosing
The total dose of CQ is 25 mg base/kg body weight over
3 days, as used for non-severe knowlesi malaria in other
studies27 and is also consistent with WHO and Malaysian
Ministry of Health guidelines for non-severe vivax
malaria. Each tablet contains 155 mg of CQ base.
Adult dose (≥35 kg): 620 mg (4 tablets) at 0 h, and
310 mg (2 tablets) at 6, 24 and 48 h.
Child dose (<35 kg): 10 mg/kg at 0 h, and 5 mg/kg at
6–8, 24 and 48 h.
Dosing schedule
The day a patient is enrolled and receives the ﬁrst dose
of medicine is designated ‘day 0’ (ﬁgure 3). All antimal-
arial treatment administration will be supervised and wit-
nessed by a study team member. Enrolled patients will
be observed for at least 30 min after treatment to ensure
they do not vomit the medicine. Any concomitant
medications will be documented in the case record form
(CRF).
Rescue medication
Should the patient vomit the ﬁrst dose of each treatment
within 1 h, this dose will be repeated. If a patient vomits
again within 1 h, or for any patient subsequently
meeting modiﬁed WHO 2010 criteria for severe
malaria21 or early treatment failure,36 the trial medica-
tion will be discontinued and rescue medication will be
initiated. Patients will receive intravenous AS 2.4 mg/kg
initially, and again at 12 and 24 h. A full course of subse-
quent oral rescue treatment will be given that will be
opposite to the trial medication administered initially.
TRIAL PROCEDURES
Appropriately qualiﬁed research medical staff will
conduct screening and enrolment of participants. This
will include clinical examination, observations and
blood sampling for laboratory investigations during
admission, and at scheduled clinic follow-up visits at 7,
14, 28 and 42 days post-treatment (see ﬁgure 4).
Research staff will also ensure patients receive proper
allocated medication dosages, monitor for adherence
and AEs and initiate rescue medication where appropri-
ate. A standardised CRF will be used to collect clinical,
biochemical and parasitological data including AEs until
the end of the individual’s study period.
Temperature
Temperature will be measured six hourly during admis-
sion and then at all follow-up visits using a consistent
method in order to evaluate fever clearance.
Parasite counts
Thick and thin blood ﬁlms for parasite counts will be
obtained via ﬁnger prick six hourly postadministration
of study medications until negative by microscopy con-
secutively over a minimum 24 h period, then at follow-up
on days 7, 14, 28 and 42. A qualiﬁed microscopist will
read all the slides independently and be blinded to treat-
ment. Slides will be cross-checked by a second expert
microscopist at a later date and parasite densities quanti-
tated by the expert microscopist will be used. Blood
Figure 2 Artesunate-mefloquine
(AS-MQ) dosing guide.
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smears with discordant results (differences between the
two microscopists in species diagnosis, in parasite density
of >50% or in the presence of parasites) will be
re-examined by a third microscopist, and parasite
density will be calculated by averaging the two closest
counts.
Blood sampling
Up to 65 mL of an adult participant’s blood, or up to
50 mL for children, will be taken in total for research
purposes during the standard study duration and sched-
ule of activities. This will include initial samples pro-
cessed for thick and thin blood ﬁlms, assessment of
glucose-6-phosphate dehydrogenase (G6PD) activity
(Beutler ﬂuorescent spot test), malaria RDTs, serological
assays and other parasitological and immunological
parameters. Haemoglobin will be assessed daily during
admission and at follow-up visits. Conﬁrmatory PCR spe-
ciation will be performed on all samples using estab-
lished methods.53–55 Drug levels for CQ and MQ using
high-pressure liquid chromatography with ultraviolet
detection will be performed on samples from days 0, 7
and 28. Blood cultures will be done on all patients in
order to exclude any concurrent blood stream infection.
All samples will be labelled anonymously, and may be
stored for a period of up to 10 years after publication of
the study. Results of blood sampling, including any other
standard laboratory or radiological investigations
ordered by the study site hospital during admission, will
be documented in the CRF.
Malaria RDTs
Pretreatment blood will be used for different malaria
RDTs in order to assess for P. falciparum histidine-rich
protein 2 (HRP2) as an exclusion criterion and to
evaluate different monoclonal antibodies against
Plasmodium parasite-lactate dehydrogenase (LDH) for
P. knowlesi detection.56–58 RDTs will include: CareStart
Pf/VOM, Humasis Pf/Pv Ag, Bionote Pf/Pv Ag, OnSite
Pf/Pv Ag, CareStart PAN. RDTs will be transported,
Figure 3 Dosing schedule.
Figure 4 Timeline of activities.
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stored and conducted according to manufacturer’s
instructions.
Pregnancy testing
Female patients of childbearing age, deﬁned as those
who menstruate or are aged over 12 years, will be asked
to take a screening urine pregnancy test before enrol-
ment in the study. CQ has limited prospective published
data in the ﬁrst trimester but is generally regarded as
safe.36 However, due to previous concerns from studies
of MQ of monotherapy in pregnant women in
Thailand,43 AS-MQ is currently not recommended
throughout pregnancy and any patients found to be
pregnant will be excluded from the study.
SAFETY EVALUATION
Treatment failure classification and management
While no treatment failures have been reported for non-
severe P. knowlesi infection, as prospective data is limited,
the conservative framework modelled on WHO deﬁni-
tions for treatment failure in P. falciparum infection will
be used.36 These treatment outcomes are classiﬁed on
the basis of an assessment of both the parasitological
and clinical outcome of antimalarial treatment. All
patients will be classiﬁed as having early treatment
failure, late clinical failure, late parasitological failure or
an adequate clinical and parasitological response.36
Adverse events
AEs and serious AEs (SAEs) are deﬁned according to
International Conference on Harmonisation (ICH)
guidelines for Good Clinical Practice (GCP).59 At each
patient encounter, a standardised system for assessing,
reporting and following up AEs and SAEs will be
adhered to as per guidelines developed by the World
Wide Antimalarial Resistance Network (WWARN).60 All
SAEs occurring during the study will have a separate
notiﬁcation form and be reported by the principal inves-
tigator to the sponsor and the study monitor.
Removal of patients from trial
Participants will be removed from the trial if informed
consent is withdrawn, or if they fail to complete treat-
ment (ie, inability to tolerate oral medication, non-
adherence to treatment regime, or develop one or more
SAEs necessitating cessation of study medicine before
completion).
Suspension or termination of the trial
The safety of both these medications is well established
and they are currently ﬁrst-line recommended Malaysian
Ministry of Health treatments.47 In addition, as these are
not new administration regimens, a safety and monitor-
ing board will not be used. Strict reporting of AEs and
SAEs will be done, with an experienced study monitor
to conduct visits before, during and at the end of the
trial. Any decision on suspending or terminating the
trial will be based on an evaluation of SAE reporting
and monitoring visits.
ANALYSIS
Clinical, biochemical and parasitological information
from standardised CRFs will be double entered into an
electronic database (EpiData, V.2.2, Denmark) to ensure
accuracy. The data will be transferred and analysed in
STATA, V.12 (StataCorp Ltd, Texas, USA).
Primary variable
The difference in the proportion of patients who are
parasite free at 24 h after treatment with AS-MQ com-
pared with CQ. This will be compared by
intention-to-treat analysis.
Secondary variables
▸ Days 28 and 42 cure rate (with and without PCR
correction).
▸ Proportion of patients with a negative slide at days 2
and 3.
▸ Parasite clearance: proportion of parasites/μL at days
1, 2 or 3 after treatment compared with baseline.
▸ Time to resolution of fever, other symptoms and clini-
cal signs.
▸ Haematological recovery as shown by incremental
change in haematocrit or haemoglobin from days 0
to 28 and days 0 to 42.
▸ Gametocyte carriage throughout 42-day study period.
▸ Progression to severe malaria (modiﬁed WHO 2010
criteria21).
▸ Sensitivity and speciﬁcity of RDTs for the diagnosis of
P. knowlesi malaria.
▸ Recurrence of any species of malaria during the
12-month follow-up period.
Overall cure rates at day 42 will be evaluated by survival
analysis with cumulative incidences calculated by
Kaplan-Meier method and also compared by the
Mantel-Haensel log-rank test. No interim analysis will be
performed.
Other data included in final analyses
(1) A description of all patients screened and reasons
for non-inclusion; (2) clinical, epidemiological and
laboratory features of all patients included in the study;
(3) the proportion of AEs and SAEs in all the patients
included in the study; (4) the proportion of patients lost
to follow-up or withdrawn, with reasons for withdrawal
and (5) length of hospital inpatient stay and estimated
cost to health sector.
Withdrawal or censoring in analysis
Patients will be withdrawn from the analysis if PCR
results are unclassiﬁable or shown not to be P. knowlesi
monoinfection. Patient’s results will be censored in the
analysis if PCR genotyping indicates any treatment
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failures are due to reinfection with P. knowlesi or new
infection with another Plasmodium species, or if con-
comitant treatments with antimalarial activity are taken
during the study period, including the initiation of
rescue medication. Any patients withdrawn from the
trial may still have data collected to that time point
included in the analysis. The extent of missing data will
be assessed and either consistent censoring of these
patients results or multiple imputation methods will be
considered.
ETHICS AND DISSEMINATION
Institutional Review Board approval
The study has been registered under http://www.
clinicaltrials.gov (#NCT01708876). Any subsequent
protocol amendments will be submitted to the ethics
committees and made available to the study monitor.
Informed consent
Patients will be included in the study only if they or
parents or guardians of participants <18 years of age give
written informed consent. Assent for those from ages 7 to
17 will be obtained in addition, as per Malaysian Medical
Research Ethics Committee (MREC) guidelines.
Informed consent will be obtained by trained study
nurses in Bahasa Malaysia or English. If the patient is illit-
erate, then thumbprint will be obtained on the consent
form in accordance with Malaysian GCP guidelines.
A consent statement for pregnancy testing is also
required for female participants of childbearing age who
are sexually active. Informed consent may be withdrawn
at any time during the study period and will have no
effect on the patient’s clinical management at the study
site. Biospecimen storage for a period of up to 10 years at
the participating institutions will be documented on the
patient information sheet and consent form. Samples will
only be used for MREC approved assays.
Confidentiality
All information on patients will remain conﬁdential and
be shared only within the research team. Unique identi-
ﬁers will be used for computer-based data entry and
blood samples. Screening forms, the case report form
and the completed identiﬁcation code list will be kept in
locked ﬁles.
Healthcare services
Any person who decides not to participate or who
cannot be enrolled into the study because he or she
does not meet the criteria will be referred for standard
Malaysian Ministry of Health management. It will be
stated clearly that a decision not to participate in the
trial will not affect subsequent care.
Reimbursement of transport
Participants in the study will be reimbursed for their
transport to attend all follow-up visits to the study sites.
Patients will be paid MYR30 for each follow-up visit. No
other gifts or payments will be made.
Trial-related injury
This is an investigator-initiated trial evaluating current
ﬁrst-line recommended standard therapies. As there is
minimal additional risk from a normal standard of care, a
trial Data Safety and Monitoring Board was not deemed
necessary. Individuals will only agree to participate after
being fully informed of inherent risks. There is no clin-
ical trial insurance and patients will not receive ﬁnancial
compensation for any trial-related injury; however,
patients will receive full access to standard Malaysian
Ministry of Health hospital and outpatient care.
Dissemination of results
At the end of the study, the principal investigator will
ﬁnalise a report on the study and its main outcome.
This report will be shared with the national malaria
control programme and the Malaysian Ministry of
Health. Results will be published in peer-reviewed
journal articles, presented at academic meetings, and
relayed to communities at Kudat, Kota Murudu and
Pitas through public meetings. All investigators will have
access to the full trial data set and be included in rele-
vant publications.
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